Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.05B | 1.10B | 1.07B | 975.10M | 1.12B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.05B | 1.10B | 1.07B | 975.10M | 1.12B |
| Cost of Revenue | 807.10M | 801.60M | 810.30M | 817.80M | 827.40M |
| Gross Profit | 242.20M | 301.30M | 262.00M | 157.30M | 290.10M |
| SG&A Expenses | 368.40M | 372.10M | 367.90M | 355.20M | 339.50M |
| Depreciation & Amortization | 65.60M | 67.30M | 65.00M | 62.90M | 59.90M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.24B | 1.24B | 1.24B | 1.24B | 1.23B |
| Operating Income | -191.80M | -138.10M | -170.90M | -260.80M | -109.30M |
| Income Before Tax | -731.20M | -738.10M | -539.40M | -376.30M | -219.00M |
| Income Tax Expenses | 29.30M | 39.90M | 62.30M | 14.60M | -7.40M |
| Earnings from Continuing Operations | -760.50 | -778.00 | -601.70 | -390.90 | -211.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -760.50M | -778.00M | -601.70M | -390.90M | -211.60M |
| EBIT | -191.80M | -138.10M | -170.90M | -260.80M | -109.30M |
| EBITDA | -70.70M | -24.10M | -40.30M | -131.80M | 15.70M |
| EPS Basic | -14.90 | -15.29 | -11.95 | -7.81 | -4.24 |
| Normalized Basic EPS | -3.33 | -2.63 | -3.04 | -3.90 | -1.98 |
| EPS Diluted | -14.91 | -15.30 | -11.96 | -7.82 | -4.24 |
| Normalized Diluted EPS | -3.33 | -2.63 | -3.04 | -3.90 | -1.98 |
| Average Basic Shares Outstanding | 204.60M | 202.60M | 200.70M | 200.00M | 200.50M |
| Average Diluted Shares Outstanding | 204.60M | 202.60M | 200.70M | 200.00M | 200.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |